I emailed Fred yesterday to ask if there would be
Post# of 30028
Is today's AVDX volume higher than normal? I'm still holding out hope that AVDX will be acquired. There are similarities to Ariosa DX before Roche acquired it in 2014.
Both were only focusing on the commercial launch of 1 Dx test. Both had only one person listed on mgmt team (i.e CEO). Both Dx tests addressed an unmet need.
I think Roche paid $625 million for Ariosa. Wouldn't surprise me if Avant went for more because of additional tests like MS Precise and Lympro. Roche is global leader in diagnostics space, and it now seems focused on areas of unmet need to grow the business.